Analyst Ratings for Alexion Pharmaceuticals (ALXN) [Buys]
ALXN Rating Summary
ALXN Price Target Summary
- Highest: $132.00 (Canaccord Genuity)
- Lowest: $90.00 (Jefferies)
- Average: $111.79
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$111.79 (+11.3%)
Avg. $ Target:
$111.79 (+11.3%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/20/2013 | Lazard Capital | Upgrade | Buy (Neutral) |
N/A (N/A) |
83.39 | 100.40 | 20.4% | Details |
| 12/13/2012 | Goldman Sachs | New Coverage | Buy (N/A) |
120.00 (N/A) |
95.09 | 100.40 | 5.58% | Details |
| 11/9/2012 | Guggenheim | New Coverage | Buy (N/A) |
121.00 (N/A) |
88.69 | 100.40 | 13.2% | Details |
| 3/26/2012 | Canaccord Genuity » Updated 9/24/2012 |
New Coverage | Buy (N/A) |
132.00 (115.00) |
93.82 | 100.40 | 7.01% | Details |
| 2/23/2012 | UBS » Updated 4/26/2013 |
Upgrade | Buy (N/A) |
123.00 (120.00) |
83.46 | 100.40 | 20.3% | Details |
| 2/10/2012 | Baird » Updated 2/15/2013 |
Upgrade | Outperform (N/A) |
125.00 (N/A) |
80.41 | 100.40 | 24.86% | Details |
| 12/9/2011 | Barclays » Updated 9/14/2012 |
New Coverage | Overweight (N/A) |
120.00 (112.00) |
64.18 | 100.40 | 56.44% | Details |
| 10/4/2011 | JPMorgan » Updated 3/21/2012 |
New Coverage | Overweight (N/A) |
105.00 (N/A) |
60.87 | 100.40 | 64.94% | Details |
| 1/18/2011 | Gleacher & Co. | Upgrade | Buy (N/A) |
N/A (N/A) |
82.37 | 100.40 | 21.89% | Details |
| 10/27/2010 | Deutsche Bank » Updated 4/22/2013 |
New Coverage | Buy (N/A) |
117.00 (N/A) |
67.61 | 100.40 | 48.5% | Details |
